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Available online 18 January 2016Background: Acute kidney injury (AKI) is associated with increased mortality, morbidity, hospital length of stay,
and costs. A quantitative urine test is available to assess the risk of developing AKI by measuring the concentra-
tions of two protein biomarkers, TIMP-2 and IGFBP-7. The NephroCheck Test combines these concentrations into
an AKIRisk Score. The purpose of this study is to characterize the analytical performance characteristics of the
AKIRisk Score.
Methods: Linearity and analytical sensitivity were evaluated by following Clinical Laboratory Standards Institute
(CLSI) EP06-A and EP17-A, respectively. Precision was evaluated by testing clinical samples and examining the
repeatability of test results. Potential interference was evaluated for endogenous and exogenous substances.
Sample stability was examined at room temperature and at 2–8 °C, as well as the effect of sample centrifugation
temperature on test results.
Results: The AKIRisk Score exhibits approximately 10% coefﬁcient of variation (CV) at the recommended cutoff
value of 0.3 and the limit of quantitation (LoQ) was 0.002. Only albumin, bilirubin (conjugated), and methylene
blue interfered with test results, at concentrations exceeding 1250 mg/L, 72 mg/L, and 0.49 mg/L, respectively.
AKIRisk Score results were stable for 6 h at room temperature, 24 h refrigerated, and not impacted by sample
centrifugation temperature.
Conclusions: Our studies demonstrate that the AKIRisk Score has robust analytical performance, good precision,
minimal analytical interference, acceptable sensitivity, and excellent sample stability.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Acute kidney injury (AKI) is a serious clinical condition that occurs
frequently without overt warning signs or symptoms, and manifests
clinically as an abrupt decrease in kidney function. AKI is often an unde-
tected, untreated, silent killer, especially in critically ill hospitalized
patients. Of the 5 million patients admitted to intensive care units
(ICUs) in the United States each year, up to 50% will develop some
form of AKI [1], and the most deadly forms of AKI (moderate–severe,
stage 2–3) can occur in 20% or more of critically ill patients [2,3].
Short-term and long-term consequences, such as length of stay (LOS),
hospital costs, 30-day readmission, and hospital mortality can be
twice as severe in patients with moderate–severe, stage 2–3 AKI [4].e inhibitor of metalloproteinase
DIGO, kidney disease improving
ospital, 75 North Country Road,
twiller-Geiger).
. This is an open access article underIn terms of incidence, AKI is as common asmyocardial infarction [5],
and studies suggest that in hospitalized patients AKI may be twice as
deadlywith death ratesmore thanbreast cancer, prostate cancer, diabe-
tes and heart failure, combined [6]. The healthcare burden for AKI is
staggering and underappreciated. In the United States, the annual eco-
nomic burden to the healthcare system for hospital-acquired AKI is
estimated to exceed $10 billion, placing it among those complications
associated with the highest in-hospital costs [7].
Until now, there have been very few options available to clinicians
for identifying patients at the highest risk for moderate to severe AKI
[5] and triaging vulnerable patients to potentially mitigate the conse-
quences of AKI. Recently, the Food and Drug Administration (FDA)
cleared the NephroCheck Test, a laboratory performed urine test to
assess the risk of developing AKI. The NephroCheck Test quantiﬁes con-
centrations of tissue inhibitor of metalloproteinase 2 (TIMP-2) and
insulin-like growth factor binding protein 7 (IGFBP-7) in urine speci-
mens. TIMP-2 and IGFPB-7 are soluble proteins expressed in the kidney
that can elevate renal tubule cell stress during the earliest, potentially
reversible, phases of injury. These two biomarkers are known to be in-
volved in the response to various tissue insults such as inﬂammation,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The two biomarkers are believed to invoke a protective mechanism
known as G1 cell-cycle arrest [8,9]. Elevation of these two biomarkers
may therefore be a signal of the kidney's attempt to protect itself
when exposed to harmful insults, thus providing a “renal alarm” that
heralds a state of high risk for imminent AKI [9].
The NephroCheck Test multiplies the concentrations of TIMP-2 and
IGFPB-7, [TIMP-2]·[IGFBP-7] / 1000 (units= (ng/ml)2 / 1000), to gener-
ate a quantitative AKI risk index (AKIRisk Score). Previous studies have
shown that in apparently healthy individuals the AKIRisk Score has a
normal reference range of 0.04 to 2.25 [10]. In hospitalized critically ill
patients, an AKIRisk Score result greater than 0.3 is associated with
seven times the risk of developing moderate to severe AKI within 12 h
of assessment, compared with patients with a less than 0.3 AKIRisk
Score [11]. The AKIRisk Score was initially developed in a discovery
study that analyzed more than 1200 diverse ICU patients from 37 clini-
cal sites in North America and Europe [8]. These two urinary biomarkers
were subsequently validated in prospective clinical trials of more than
500 diverse ICU patients from 29 clinical sites in the United States [11,
12]. Because the NephroCheck Test is the ﬁrst of its kind for risk assess-
ment of AKI, there is no predicate test, and the AKIRisk Score was there-
fore validated by comparison to a clinical endpoint rather than in a
method comparison. The primary endpoint was moderate–severe
(stage 2–3) AKI within the 12 h after sample collection as determined
by clinical adjudication among a committee of three nephrologists
based on Kidney Disease Improving Global Outcomes (KDIGO) Consen-
sus criteria [13]. We report here, for the ﬁrst time, the analytical perfor-
mance characteristics of the NephroCheck Test and AKIRisk Score. We
speciﬁcally examined the analytical linearity, precision, sensitivity, and
robustness of the AKIRisk Score to potentially interfering substances,
as well as sample handling and storage conditions.
2. Materials and methods
2.1. Test method
The NephroCheck Test quantitatively measures TIMP-2 and protein
IGFBP-7 concentrations in adult, human urine in approximately
20 min using ﬂuorescence, lateral ﬂow immunoassay technology [14].
The test contains sandwich immunoassays for TIMP-2 and IGFBP-7 in
a single-use plastic test cartridge. Urine samples are centrifuged,
added to a buffer, and mixed with a ﬂuorescent antibody conjugate
prior to measurement.
The sample is then applied to the cartridge and inserted into a
bench-top instrument that reads the ﬂuorescent signals from each
of the TIMP-2 and IGFBP-7 immunoassays. The test system displays
the immunoassay results as a single numerical result called the
AKIRisk Score. The AKIRisk Score result is calculated from the multi-
plicative product of the two biomarker results divided by 1000
(i.e.[TIMP-2]·[IGFBP-7]/1000) [14]. The AKIRisk Score has units of
(ng/ml)2 /1000, but is presented as a dimensionless result by the
test system, and as such, the AKIRisk Score was analyzed and is re-
ported without units in our studies.
2.2. Analytical sensitivity
The limit-of-blank (LoB), limit-of-detection (LoD), and limit-of-
quantitation (LoQ) for the TIMP-2, IGFBP-7, and AKIRisk Score results
were determined following CLSI guideline EP17-A [15]. A blank urine
sample devoid of TIMP-2 and IGFBP-7 was tested with 72 individual
NephroCheck Tests. The LoB was given by the 95th percentile of the
blank sample results. LoD and LoQwere evaluated by separately testing
6 urine samples, containing low concentrations of TIMP-2 and IGFBP-7,
with 36 individual NephroCheck Tests per sample across 3 days of test-
ing, 2 test runs per day, 6 replicates per test run. The LoD was deter-
mined from the lowest concentration urine sample that exhibited lessthan 5% chance of falsely concluding that no analyte was present in
the sample. The LoQ was determined from the lowest concentration
urine sample that exhibited assay results with less than 20% total
error in the TIMP-2 and IGFBP-7 assay results.
2.3. Precision study
Precision of the AKIRisk Score was evaluated by testing 1123 urine
specimens collected from critically ill hospitalized patients at risk for
AKI. These samples were previously collected as part of the Topaz mul-
ticenter study and followed the Helsinki Declaration of human rights
[11]. The study was approved and participants provided written in-
formed consent. Each samplewas tested in singlicate across different in-
struments, operators, and testing runs at three different laboratories to
collect a total of 3369 data points. Outliers, representing 1.2% of the data
or 39 data points, were removed from this dataset according to Healy's
test for outliers [16]. The remaining data were used to construct a preci-
sion proﬁle according to previously publishedmethods [17]. Brieﬂy, the
average AKIRisk Score result for each sample was calculated among the
three testing laboratories. The results for all samples were then sorted
by these average values in ascending order and grouped into bins of
20 to 50 samples. The CV and average AKIRisk Score within each bin
were calculated and plotted against one another to examine the AKIRisk
Score's CV as a function of its reported value.
2.4. Linearity studies
The linearity of the TIMP-2 and IGFBP-7 assays was evaluated fol-
lowing CLSI guideline EP06-A [18]. A single urine sample that contained
elevated concentrations of both biomarkers was mixed with a separate
urine sample that contained low concentrations of both biomarkers.
These samples weremixed to prepare 9 test samples with IGFBP-7 con-
centrations between 3.9 and 543.6 ng/ml and TIMP-2 concentrations
between 0.9 and 36.0 ng/ml. Each concentration was tested with at
least 9 individual NephroCheck Tests. TIMP-2 and IGFBP-7 assay results
were compared against their expected values with second and third
order polynomial regression models to evaluate linearity.
2.5. Interference studies
The effect of 127 potential interfering substances (Table 1)was eval-
uated following CLSI guideline EP07-A2 [19]. Each substance was tested
at multiple therapeutic or clinically relevant concentrations of the
interferent. At each test concentration, the substance was added to a
human urine pool that contained approximately 3.5–3.9 ng/ml TIMP-2
and 80.8–92.0 ng/ml IGFBP-7. This urine test sample and a correspond-
ing control urine sample devoid of the potential interferents were then
testedwith at least 32 individualNephrocheck Tests. Any substance that
exhibited more than a 10% bias in AKIRisk Score results between test
and control samples or consistently gave an “invalid”message on the in-
strument display was considered to interfere with test results.
In addition to the above testing, albumin and bilirubin (conjugated)
levels were alsomeasured in urine samples collected from 388 critically
ill ICU adult subjects at risk for AKI. These samples were previously col-
lected as part of the Topaz multicenter study as described above [11].
Data from this analysis were used to understand the prevalence of po-
tential albumin and bilirubin (conjugated) interferences. These mea-
surements were conducted by an independent reference lab (ARUP
Laboratories, Salt Lake City, UT) using Roche ALBT2 (albumin) and
TBILI (total bilirubin) assays.
2.6. Sample stability studies
The stability of the AKIRisk Scorewith respect to sample storagewas
evaluated with 126 urine samples collected from critically ill ICU adult
subjects at risk for AKI. These samples were collected as part of the
Table 1
Endogenous and exogenous substances tested for interference with the AKIRisk Score.
Dextran 40 Ethacrynic acid Pancuronium
Pentastarch Ethanol Pantoprazole (protonix)
Hetastarch Fenoldopam Phenobarbital
Visipaque (iodixanol) Fentanyl Phenylephrine
Omniscan
(gadodiamide)
Fluconazole Pravastatin
Omnipaque (iohexol) Fluvastatin Prednisone (prednisolone)
Magnevist Furosemide Propofol
(Gadopentate
dimeglumine)
Gentamicin Ranitidine
Optiray (ioversol) Glucose Riboﬂavin
Acetaminophen Hemoglobin Rocuronium
Acetone Heparin Theophylline
Acetylcysteine albumin Hydralazine Tobramycin
Aspirin Hydrochlorothiazide Torsemide
Acyclovir Hydrocodone Urobilinogen
Albuterol Hydrocortisone Valproic acid (valproate)
Amiodarone Ibuprofen Vancomycin
Ammonia Insulin Vasopressin
Amoxicillin Ketorolac Vecuronium
Amphotericin Lansoprazole Warfarin (coumadin)
Ascorbic acid Linezolid Cystatin C
Atorvastatin Lisinopril Interleukin-18 (IL-18)
Bicarbonates bilirubin
(conjugated)
Lorazepam Kidney injury molecule 1
Bumetanide Low molecular
weight heparin
Liver type fatty acid binding
protein
Caffeine Mannitol N-acetyl-β-D-glucosaminidase
Caspofungin Metformin Neutrophil gelatinase associated
lipocalin (NGAL)
Cefepime Methylene blue Pi-glutathione s-transferase
Ceftriaxone Metolazone Calcium
Cephalexin Metoprolol Chloride
Ciproﬂoxacin Metronidazole Creatinine
Clopidogrel Midazolam Magnesium
Dexmedetomidine Morphine Phosphate
Diltiazem Moxiﬂoxacin
myoglobin
Potassium
Dopamine Nitroglycerin Sodium
Doripenem Norepinephrine Sulfate
Epinephrine Omeprazole Urea
Ondanesteron Uric Acid
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rights [12]. The study was approved and participants provided written
informed consent. Each sample was tested in duplicate within 2 h of
collection time to allow for transport of the sample to the laboratory.
Separate aliquots of each of these samples were then tested in duplicate
after storage at the following conditions: 6±1 h at ambient lab temper-
atures and 24 ± 4 h at 2–8 °C. A weighted Deming regression analysis
was used to compare AKIRisk Score results from each of these storageFig. 1. Precision proﬁle of theAKIRisk Score based on repeatedmeasurements of 1123 clinical sp
Score across the reportable range of 0.04-10.00 and (B) near the recommended cutoff value ofconditions with the corresponding data generated within 2 h of sample
collection.
The stability of theAKIRisk Scorewith respect to urine centrifugation
temperature was evaluated with 127 remnant (otherwise medical
waste) urine samples collected from ICU patients. An aliquot of each
samplewas tested in duplicate after centrifugation in a refrigerated cen-
trifuge set to 4 °C. A separate aliquot of each sample was also tested in
duplicate after centrifugation at ambient lab temperatures. A weighted
Deming regression analysis was used to compare AKIRisk Score results
obtained after room temperature centrifugationwith the corresponding
results obtained after refrigerated centrifugation.3. Results
3.1. Precision
Testing of 1123 clinical samples collected from critically ill ICU pa-
tients at risk for AKI across multiple laboratories yielded the precision
proﬁle for the AKIRisk Score results illustrated in Fig. 1. This precision
proﬁle exhibits an average CVof 11% across all samples. Near the recom-
mendedAKIRisk Score cutoff of 0.3, the AKIRisk Score result exhibits ap-
proximately 10% CV. The imprecision of the AKIRisk Score result
increases near the bottom of the reportable range, with approximately
15% CV near the minimum reportable AKIRisk Score result of 0.04.3.2. Analytical sensitivity
The analytical sensitivity characteristics of the NephroCheck Test are
presented in Table 2. The AKIRisk Score exhibited a LoQ value of 0.002,
well below its reportable range of 0.04 to 10.0 and recommended clini-
cal cutoff value of 0.3.3.3. Linearity
The NephroCheck Test exhibited linear TIMP-2 and IGFBP-7 assay re-
sults as shown in Table 3. Best ﬁt second and third order non-linear re-
gression analyses of these data produced statistically insigniﬁcant
(p N 0.05) nonlinear regression coefﬁcients indicating that the TIMP-2
and IGFBP-7 assay results are linear. The data in Table 3 demonstrate
linearity between 0.9 and 36.0 ng/ml for TIMP-2 and 3.9 and
543.6ng/ml for IGFBP-7. This corresponds toAKIRisk Score values ranging
from 0.003 to 19.6. Additionally, observed TIMP-2 and IGFBP-7 assay re-
sultswerewithin 10% of their expected values for all test samples, further
demonstrating the linearity of the these results.ecimens at three different laboratories. (A) The Total CV is shownas function of theAKIRisk
0.30.
Table 2
Limit-of-blank (LoB), limit-of-detection (LoD), and limit-of-quantitation (LoQ) of the
NephroCheck Test's TIMP-2, IGFBP-7, and AKIRisk Score results.
Result LoB LoD LoQ
TIMP-2 0.5 ng/ml 0.7 ng/ml 0.7 ng/ml
IGFBP-7 0.4 ng/ml 2.8 ng/ml 2.8 ng/ml
AKIRisk Score 0.0002 0.002 0.002
96 D.L. Uettwiller-Geiger et al. / Clinica Chimica Acta 455 (2016) 93–983.4. Interference
The 127 substances listed in Table 1 were evaluated for interference.
Albumin, bilirubin (conjugated), andmethylenebluewere the only sub-
stances that interfered with test results. These substances impacted
AKIRisk Score results at concentrations exceeding 1250 mg/L, 72 mg/L,
and 0.49 mg/L, respectively. No other substances exhibited signiﬁcant
interference.
Elevated urine concentrations of albumin, bilirubin (conjugated),
and methylene blue were further tested to characterize how these sub-
stances interferewith test results. The outcome of this additional testing
is presented in Table 4. Albumin concentrations listed in Table 4 exceed-
ing 1250 mg/L (i.e. ≥2500 mg/L) increased AKIRisk Score results by 15%
to 30%. Albumin concentrations of 30,000 mg/L lead to an “invalid”
message on the meter rather than a quantitative AKIRisk Score result.
Conjugated bilirubin concentrations listed in Table 4 greater than
72 mg/L decreased IGFBP-7, TIMP-2, and AKIRisk Score results by 10%
to 20%. Like albumin, elevated methylene blue concentrations listed in
Table 4 exceeding 0.49 mg/L lead to an “invalid” message on the
meter rather than a quantitative AKIRisk Score result.
To understand the prevalence of the albumin and bilirubin (conju-
gated) interferences, we analyzed urine samples collected from 388 pa-
tients at risk for AKI. These patients suffered from conditions associated
with elevated urine albumin, including patients with chronic kidney
disease (8%), diabetes (29%), and hypertension (67%). Additionally,
this population included patients who suffered from disease conditions
associated with elevated bilirubin (conjugated) levels such as liver dis-
ease (7%), hepatic failure (2.1%), and cirrhosis (5%). Study results reveal
that fewer than 2% of these urine samples had albumin levels that
exceeded the concentrations observed to cause interference, and none
of these urine samples had bilirubin (conjugated) concentrations
observed to cause interference.3.5. Sample stability
AKIRisk Score results were stable at the ambient and refrigerated
sample storage conditions examined. As illustrated in Fig. 2A and B,
AKIRisk Score results from 124 critically ill ICU patients obtained after
6 h ambient sample storage and 24 h refrigerated sample storage
were equivalent to the corresponding results obtained shortly after
sample collection (i.e. within 2 h of sample collection). RegressionTable 3
Linearity and relative accuracy of the NephroCheck Test's TIMP-2 and IGFBP-7 assays.
IGFBP-7
Expected conc.
(ng/ml)
Observed conc.
(ng/ml)
%
recovery
Polynomial regression coefﬁcients
p-values
3.87 3.87 100.0% Second order (×2) p = 0.17
Third order (×2) p = 0.25
Third order (×3) p = 0.35
78.87 71.34 90.5%
146.71 138.82 94.6%
213.17 206.29 96.8%
276.26 273.76 99.1%
350.74 341.23 97.3%
408.73 408.7 100.0%
474.48 476.17 100.4%
543.64 543.64 100.0%analyses of the plotted data indicate that AKIRisk Score results change
by 1.3% on average after 6 h ambient storage and 2.9% on average
after 24 h refrigerated storage. Additionally, the intercept and slope
values from all regression analyses were not statistically signiﬁcant
(p N 0.05 for intercept and slope values based on a null hypotheses
slope = 1 and intercept = 0).
AKIRisk Score results were also stable with respect to centrifuga-
tion temperature. The instructions provided with the NephroCheck
Test instruct users to centrifuge urine samples in a refrigerated cen-
trifuge prior to testing [14]. Our results indicate that samples are sta-
ble at ambient centrifugation temperatures. As illustrated in Fig. 2C,
AKIRisk Score results from 127 ICU patient samples obtained after
ambient centrifugation were equivalent to the corresponding results
obtained after centrifugation under refrigerated conditions. The re-
gression analysis of the data shown in Fig. 2C indicate that AKIRisk
Score results differ by 1.3% on average between ambient and refrig-
erated centrifugation procedures. Additionally, the intercept and
slope values from this regression analysis were not statistically sig-
niﬁcant (p N 0.05 for intercept and slope values based on a null hy-
potheses of intercept = 0 or slope = 1).
4. Discussion
TheNephrocheck Test providesAKIRisk Score results that are analyt-
ically accurate and reproducible. The precision study analyzed clinical
specimens from 1123 critically ill patients at risk for AKI and demon-
strated good reproducibility of theAKIRisk Score result. The total impre-
cision (CV), accounting for within-run, run-to-run, site-to-site,
instrument-to-instrument, and operator-to-operator sources of vari-
ability, is 10% to 15% across the AKIRisk Score's reportable range of
0.04 to 10.0. The total imprecision of the AKIRisk Score at the recom-
mended cutoff of 0.3 was 10%.
Analytical sensitivity and linearity study results indicate that the
AKIRisk Score has good analytical sensitivity and provides quantitative-
ly accurate results throughout its reportable range. The LoQ of the
AKIRisk Score is 20-fold lower than its minimum reportable value of
0.04, demonstrating that has sufﬁcient analytical sensitivity to support
its reportable range of 0.04 to 10.0. Furthermore, TIMP-2 and IGFBP-7
results are linear and therefore possess good internal and relative accu-
racy. Although the AKIRisk Score itself is not linear since it is the multi-
plicative product of two linear results, it exhibits good internal and
relative accuracy given the linearity of its constituent TIMP-2 and
IGFBP-7 results.
Interference studies examined the effect of 127 potentially interfer-
ing substances relevant to patients at risk for AKI. Only three of these
substances exhibited interference. Albumin, bilirubin (conjugated),
and methylene blue interfered with test results at the concentrations
listed in Table 4 exceeding 1250 mg/L, 72 mg/L, and 0.49 mg/L, respec-
tively. The interferences observed with bilirubin (conjugated) and
methylene blue may be caused by interference between the optical
properties of these materials and the ﬂuorescent reagents containedTIMP-2
Expected conc.
(ng/ml)
Observed conc.
(ng/ml)
%
recovery
Polynomial regression coefﬁcients
p-values
0.94 0.94 100% Second order (×2) p = 0.54
Third order (×2) p = 0.18
Third order (×3) p = 0.14
5.59 5.32 95%
10.31 9.69 94%
14.68 14.07 96%
18.97 18.45 97%
23.17 22.83 99%
27.7 27.21 98%
31.39 31.58 101%
35.96 35.96 100%
Table 4
Characterization of Albumin, Bilirubin (conjugated) and Methylene Blue Interference.
Albumin conc. (mg/L) % recovery IGFBP-7 conc. % recovery TIMP-2 conc. % recovery AKIRisk conc.
1250 102.1 100.7 103.1
2500 117.5 108.3 128.6
5000 115.9 103.4 119.8
15,000 125.9 103.1 129.7
30,000 No resulta No resulta No resulta
Bilirubin (conjugated) conc. (mg/L) % recovery IGFBP-7 conc. % recovery TIMP-2 Conc. % recovery AKIRisk
72 99.1 101.9 101.1
145 89.5 88.7 79.1
217 84.5 88.1 74.3
289 86.5 91.2 79.1
Methylene blue conc. (mg/L) % recovery IGFBP-7 conc. % recovery TIMP-2 conc. % recovery AKIRisk
0.49 100.0 98.3 98.2
1.95 No resulta No resulta No resulta
2.93 No resulta No resulta No resulta
a When no result is reported, the test instrument displayed an “invalid”message rather than a quantitative test result.
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ence observed with albumin may be caused by albumin's impact on
urine viscosity. It has been reported that high concentrations of albumin
increases urine viscosity [20]. This increased viscosity may slow sample
ﬂow through the test's lateral ﬂow membrane and thereby impact test
results.
Methylene blue is a substance approved for intravenous use to treat
methemoglobinopathies [21] and functions to reduce methemoglobin
back to hemoglobin. It is also used off label for imaging procedures
[22] and to treat low systemic resistance and increased cardiac output
following cardiac surgery [23]. As methylene blue causes urine to turn
blue, a visual inspection of the urine sample for a blue color would be
an indicator of this potential interferent [24].We found that the test sys-
tem was able to detect methylene blue interference. When methylene
blue interfered with results, the test system displayed an “invalid”
message on the meter and no quantitative test result was reported.
Since the presence of methylene blue in urine is visually obvious and
the instrument displays an “invalid”message when methylene blue in-
terference is present, we conclude thatmethylene blue interferencewill
have little clinical impact.
Unlikemethylene blue, both albumin and bilirubin (conjugated) are
naturally occurring substances in the body. Normal levels of albumin in
urine range from 0 to 80mg/L [20]. Urine albumin levels may be elevat-
ed above this range in clinical populations with chronic kidney disease,
diabetes, glomerular disease, and hypertension [25]. While conjugated
bilirubin is normally not present in urine [26]; urine bilirubin (conjugat-
ed) may be elevated in patients with liver damage or dysfunction [27].
Unlike methylene blue, the presence of albumin or bilirubin may not
be obvious in urine samples because these substances donot necessarily
change the visual appearance of urine and the test does not necessarily
report an “invalid” AKIRisk Score result when albumin or bilirubin
(conjugated) interferences are present.
Although albumin and bilirubin (conjugated) can interfere with test
results, we found that concentrations that would cause interference are
seldom present in patients at risk for AKI. We analyzed urine albumin
and bilirubin (conjugated) concentrations in samples collected from
388 patients at risk for AKI. Fewer than 2% of patients had albuminFig. 2(A) A comparison of the AKIRisk score results from samples obtained within 2 hours
of sample collection (fresh samples; x-axis) and the same samples obtained after 6 hours
of storage at ambient temperatures (y-axis). (B) A comparison of the AKIRisk score results
from samples obtainedwithin 2 hours of sample collection (fresh samples; x-axis) and the
same samples obtained after 24 hours storage at 2-8⁰C (y-axis). (C) A comparison of the
AKIRisk score results from 127 patient samples centrifuged at ambient (x-axis) and refrig-
erated (y-axis) temperatures.
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ited elevated bilirubin (conjugated) concentrations.
The sample stability study demonstrates that AKIRisk Score results
exhibit good sample stability. Urine samples may be stored for up to
6 h at room temperature and 24 h at refrigerated conditions. This stabil-
ity is sufﬁcient to support the intended use of the NephroCheck Test. In
particular, the test is intended to be used for risk assessment of moder-
ate or severe kidney injury within 12 h of sample collection and patient
assessment [14]. Based on this intended use, clinicians have a limited
time period (i.e. no longer than 12 h from sample collection) to act
upon the AKIRisk Score results [14]. Therefore, although our results in-
dicate that urine samplesmay be stored for 6 ormore hours, clinical lab-
oratories should avoid prolonged urine sample storage and test urine
samples as soon as possible to maximize the clinical risk assessment
value of the AKIRisk Score result and its impact on patient care.
Additional stability studies show that the AKIRisk Score result is also
stable at ambient centrifugation temperatures. Centrifugation of urine
samples prior to analysis is generally recommended to remove any sed-
iment, casts, or other solidmaterials in the urine thatmay interferewith
test results [24]. The test's instructions-for-use state that urine samples
should be refrigerated during centrifugation [14]. However, our results
indicate that refrigerated and ambient centrifugation yield equivalent
AKIRisk Score test results. Therefore, refrigerated centrifugation of
urine samples prior to analysis is unnecessary, and urine samples may
be centrifuged at ambient temperatures with no negative impact on
test results.
In conclusion, the NephroCheck Test is the ﬁrst FDA cleared test to
assess risk of developing acute kidney injury. Our studies demonstrate
that the results of this test have good precision, acceptable analytical
sensitivity, minimal analytical interference, and are robust to sample
handling and processing conditions.
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